Sigma Planning Corp lowered its stake in Pfizer Inc. (NYSE:PFE) by 1.4% during the second quarter, HoldingsChannel reports. The firm owned 138,493 shares of the biopharmaceutical company’s stock after selling 2,020 shares during the period. Sigma Planning Corp’s holdings in Pfizer were worth $6,000,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Evolution Wealth Advisors LLC acquired a new stake in Pfizer during the 2nd quarter worth about $34,000. IMA Wealth Inc. boosted its position in Pfizer by 144.5% during the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 477 shares during the period. Winch Advisory Services LLC boosted its position in Pfizer by 69.6% during the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 336 shares during the period. Ruggie Capital Group acquired a new stake in Pfizer during the 4th quarter worth about $44,000. Finally, Financial Gravity Wealth Inc. boosted its position in Pfizer by 33.2% during the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 257 shares during the period. Hedge funds and other institutional investors own 71.81% of the company’s stock.

Pfizer stock traded up $0.17 on Friday, reaching $34.65. The company’s stock had a trading volume of 28,267,400 shares, compared to its average volume of 34,506,988. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.27 and a current ratio of 1.47. The company has a market cap of $190.71 billion, a price-to-earnings ratio of 11.55, a PEG ratio of 2.75 and a beta of 0.63. The business’s fifty day moving average price is $40.84 and its 200 day moving average price is $41.69. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $46.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.05. The company had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The business’s revenue was down 1.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.77 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.8 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be paid a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 4.16%. The ex-dividend date of this dividend is Thursday, August 1st. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

In other news, EVP Frank A. Damelio sold 153,184 shares of the company’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the transaction, the executive vice president now owns 489,647 shares of the company’s stock, valued at $21,588,536.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 30,000 shares of the company’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total value of $1,320,000.00. Following the transaction, the insider now directly owns 80,094 shares in the company, valued at approximately $3,524,136. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

PFE has been the subject of a number of research reports. UBS Group restated a “neutral” rating and set a $43.00 price objective on shares of Pfizer in a research report on Monday, August 5th. JPMorgan Chase & Co. set a $46.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Monday, July 29th. Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 30th. Barclays restated a “hold” rating and set a $41.00 price objective on shares of Pfizer in a research report on Thursday, May 9th. Finally, Goldman Sachs Group restated a “buy” rating and set a $49.00 price objective on shares of Pfizer in a research report on Monday, June 17th. Fourteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $46.56.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: What is quantitative easing?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.